MA30665B1 - Traitement de maladies rhumatoïdes avec des glucocorticoïdes a liberation retardee. - Google Patents

Traitement de maladies rhumatoïdes avec des glucocorticoïdes a liberation retardee.

Info

Publication number
MA30665B1
MA30665B1 MA31665A MA31665A MA30665B1 MA 30665 B1 MA30665 B1 MA 30665B1 MA 31665 A MA31665 A MA 31665A MA 31665 A MA31665 A MA 31665A MA 30665 B1 MA30665 B1 MA 30665B1
Authority
MA
Morocco
Prior art keywords
treatment
delayed release
rheumatoid diseases
glucocorticoids
release glucocorticoids
Prior art date
Application number
MA31665A
Other languages
English (en)
Inventor
Achim Schaeffler
Original Assignee
Nitec Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38739340&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30665(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nitec Pharma Ag filed Critical Nitec Pharma Ag
Publication of MA30665B1 publication Critical patent/MA30665B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne le traitement d'une maladie rhumatismale et/ou d'arthrose par l'administration d'une forme dosée à libération retardée d'un glucocorticoïde à un patient en ayant besoin.
MA31665A 2006-08-03 2009-02-26 Traitement de maladies rhumatoïdes avec des glucocorticoïdes a liberation retardee. MA30665B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83509306P 2006-08-03 2006-08-03

Publications (1)

Publication Number Publication Date
MA30665B1 true MA30665B1 (fr) 2009-08-03

Family

ID=38739340

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31665A MA30665B1 (fr) 2006-08-03 2009-02-26 Traitement de maladies rhumatoïdes avec des glucocorticoïdes a liberation retardee.

Country Status (27)

Country Link
US (5) US20080076743A1 (fr)
EP (1) EP2049123B2 (fr)
JP (1) JP2009545546A (fr)
KR (1) KR101430089B1 (fr)
CN (1) CN101466385B (fr)
AU (1) AU2007280636B2 (fr)
BR (1) BRPI0717052A2 (fr)
CA (1) CA2655682A1 (fr)
DK (1) DK2049123T4 (fr)
EA (1) EA015304B1 (fr)
ES (1) ES2400446T5 (fr)
HK (1) HK1130423A1 (fr)
HR (1) HRP20130148T4 (fr)
IL (1) IL195155A (fr)
MA (1) MA30665B1 (fr)
MX (1) MX2009001248A (fr)
MY (1) MY149863A (fr)
NO (1) NO20090958L (fr)
PL (1) PL2049123T5 (fr)
PT (1) PT2049123E (fr)
RS (1) RS52672B2 (fr)
SG (2) SG174026A1 (fr)
SI (2) SI2049123T2 (fr)
TN (1) TNSN08385A1 (fr)
UA (1) UA96457C2 (fr)
WO (1) WO2008015018A1 (fr)
ZA (1) ZA200809858B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2049123E (pt) 2006-08-03 2013-03-06 Horizon Pharma Ag Tratamento de doença reumatóide com glucocorticóide de libertação retardada
TWI494108B (zh) * 2009-01-26 2015-08-01 Nitec Pharma Ag 糖皮質激素用以製備嚴重夜間氣喘用之於延遲釋放型的藥物之用途
NZ582836A (en) * 2009-01-30 2011-06-30 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage
US9522263B2 (en) * 2010-04-28 2016-12-20 Kimberly-Clark Worldwide, Inc. Device for delivery of rheumatoid arthritis medication
WO2013053767A1 (fr) * 2011-10-10 2013-04-18 Medimmune Limited Traitement de la polyarthrite rhumatoïde
GB201202433D0 (en) 2012-02-13 2012-03-28 Diurnal Ltd Controlled drug release
US9012432B2 (en) * 2013-03-08 2015-04-21 Levolta Pharmaceuticals, Inc. Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis

Family Cites Families (173)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3048526A (en) 1958-08-04 1962-08-07 Wander Company Medicinal tablet
GB972128A (en) 1960-01-21 1964-10-07 Wellcome Found Pellets for supplying biologically active substances to ruminants and the manufacture of such pellets
BE629982A (fr) 1962-04-06
FR1603314A (en) 1965-02-23 1971-04-05 Pharmaceutical tablets - having a core and a matrix material
US3870790A (en) 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
FR2100858B1 (fr) 1970-07-03 1975-06-06 Daiichi Seiyaku Co
DE2445971A1 (de) 1974-09-24 1976-04-08 Schering Ag Arzneimittelwirkstofftraeger ii
US4797288A (en) 1984-10-05 1989-01-10 Warner-Lambert Company Novel drug delivery system
GB8518301D0 (en) 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
US5519057A (en) 1986-11-14 1996-05-21 Johnson & Johnson--Merck Pharmaceuticals Co. Ibuprofen-containing medicament
IT1201136B (it) 1987-01-13 1989-01-27 Resa Farma Compressa per uso farmaceutico atta al rilascio in tempi successivi di sostanze attive
GB8705083D0 (en) 1987-03-04 1987-04-08 Euro Celtique Sa Spheroids
GB8820353D0 (en) 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
US5047246A (en) 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
IT1230576B (it) 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
US4966770A (en) 1989-07-26 1990-10-30 Himedics, Inc. Prednisone microencapsulated granules
DE3930770A1 (de) 1989-09-14 1991-03-28 Wolfgang F Dr Schoener Implantierbare katheter aus medizinisch vertraeglichem elastischen kunststoff
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
JP2558396B2 (ja) 1990-06-28 1996-11-27 田辺製薬株式会社 放出制御型製剤
JP2521848B2 (ja) 1990-07-02 1996-08-07 ベーリンガー マンハイム ゲーエムベーハー 成形され、圧縮された徐放性単位投薬形態の調製法およびこうして得られた圧縮単位投薬形態
ATE105710T1 (de) 1990-07-02 1994-06-15 Boehringer Mannheim Gmbh Verfahren zur herstellung geformter, verpresster dosiseinheiten mit retardierter freisetzung und entsprechende dosiseinheit.
IE61651B1 (en) 1990-07-04 1994-11-16 Zambon Spa Programmed release oral solid pharmaceutical dosage form
US5310578A (en) 1990-09-17 1994-05-10 Merck Patent Gesellschaft Deposition of cosmetically functional material onto pigments and fillers
US5316772A (en) 1990-12-19 1994-05-31 Solvay & Cie, S.A. (Societe Anonyme) Bilayered oral pharmaceutical composition with pH dependent release
ES2060465T3 (es) 1991-01-03 1994-11-16 Glaxo Canada Procedimiento para la produccion de preparacion farmaceutica solida.
DE4100920A1 (de) * 1991-01-15 1992-07-16 Degussa Wirkstoffzubereitung zur oralen verabreichung an wiederkaeuer
EP0546593B1 (fr) 1991-10-30 1997-09-03 Glaxo Group Limited Compositions multicouches contenant d'antagonistes de l'histamine ou de la sérotonine
WO1993019741A1 (fr) 1992-03-31 1993-10-14 Benzon Pharma A/S Formulation pharmaceutique
GB9215908D0 (en) 1992-07-27 1992-09-09 Wellcome Found Water dispersible tablets
WO1994007470A1 (fr) 1992-09-30 1994-04-14 Pfizer Inc. Article contenant un noyau et un revetement d'epaisseur non constante
WO1994008589A1 (fr) 1992-10-09 1994-04-28 The Board Of Trustees Of The Leland Stanford Junior University Traitement du lupus erythemateux systemique a la deshydroepiandrosterone
TW272942B (fr) 1993-02-10 1996-03-21 Takeda Pharm Industry Co Ltd
DK66493D0 (da) 1993-06-08 1993-06-08 Ferring A S Praeparater, isaer til brug ved behandling af inflammatoriske tarmsygdomme eller til at opnaa forbedret saarheling
IL110376A (en) 1993-08-02 1998-08-16 Bristol Myers Squibb Co Pharmaceutical preparations containing iftroban and methods for their preparation
DE4332394A1 (de) 1993-09-23 1995-03-30 Falk Pharma Gmbh Budesonid-Pellets mit kontrolliertem Freigabeprofil und Verfahren zu ihrer Herstellung
US5482718A (en) 1994-03-23 1996-01-09 Hoffmann-La Roche Inc. Colon-targeted delivery system
US5464633A (en) 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
US5702723A (en) 1994-08-02 1997-12-30 Griffin; David Multi-stage delivery system for ingestible medications or nutrients
US5811388A (en) 1995-06-07 1998-09-22 Cibus Pharmaceutical, Inc. Delivery of drugs to the lower GI tract
US5709880A (en) 1995-07-10 1998-01-20 Buckman Laboratories International, Inc. Method of making tabletized ionene polymers
IT1276031B1 (it) 1995-10-31 1997-10-24 Angelini Ricerche Spa Composizione farmaceutica per il trattamento delle malattie autoimmuni
JP3220373B2 (ja) 1995-11-28 2001-10-22 バイエル薬品株式会社 持続性ニフエジピン製剤
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840332A (en) 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
WO1997027843A2 (fr) 1996-01-30 1997-08-07 Advanced Polymer Systems, Inc. Apport cible de medicaments sur la partie inferieure du tractus gastro-intestinal
IT1282576B1 (it) 1996-02-06 1998-03-31 Jagotec Ag Compressa farmaceutica atta a cedere la sostanza attiva in tempi successivi e predeterminabili
HRP970493A2 (en) * 1996-09-23 1998-08-31 Wienman E. Phlips Oral delayed immediate release medical formulation and method for preparing the same
AU744156B2 (en) 1996-10-28 2002-02-14 General Mills Inc. Embedding and encapsulation of controlled release particles
US5792476A (en) * 1996-12-19 1998-08-11 Abigo Medical Ab Sustained release glucocorticoid pharmaceutical composition
US5788987A (en) 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
US6210710B1 (en) 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
EA002482B1 (ru) 1997-07-01 2002-06-27 Пфайзер Инк. Соли сертралина и лекарственные формы с длительным высвобождением сертралина
US6013280A (en) 1997-10-07 2000-01-11 Fuisz Technologies Ltd. Immediate release dosage forms containing microspheres
WO1999018938A1 (fr) 1997-10-09 1999-04-22 Perio Products Ltd. Systeme d'administration de medicaments a liberation totale prolongee destines au tractus gastro-intestinal
US7201923B1 (en) 1998-03-23 2007-04-10 General Mills, Inc. Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles
US6365185B1 (en) * 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
EP1067910B1 (fr) 1998-04-03 2004-05-26 Egalet A/S Composition a liberation controllee
US6602521B1 (en) 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
US6375986B1 (en) 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
EP1027888B1 (fr) 1999-02-10 2009-06-10 Pfizer Products Inc. Dispositif osmotique pour délivrer des dispersions solides amorphes des médicaments
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
GB9905898D0 (en) * 1999-03-15 1999-05-05 Darwin Discovery Ltd Controlled-dose formulation
US6677326B2 (en) 1999-03-15 2004-01-13 Arakis, Ltd. Corticosteroid formulation comprising less than 2.5 mg prednisolone for once daily administration
US6245352B1 (en) 1999-04-27 2001-06-12 Eli Lilly And Company Pharmaceutical formulation
JP2001010950A (ja) 1999-06-29 2001-01-16 Taiyo Yakuhin Kogyo Kk 安定で良好な薬物放出を有する医薬組成物
US6458383B2 (en) 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US6500459B1 (en) 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
EP1074249A1 (fr) 1999-07-27 2001-02-07 Jagotec Ag Système de comprimé pharmaceutique pour la libération d' au moins une substance active pendant une période de libération après une période de non -libération
US6428809B1 (en) 1999-08-18 2002-08-06 Microdose Technologies, Inc. Metering and packaging of controlled release medication
AR026148A1 (es) 2000-01-21 2003-01-29 Osmotica Argentina S A Dispositivo osmotico con pasaje preformado que aumenta de tamano
DE10012555A1 (de) 2000-03-15 2001-09-20 Merck Patent Gmbh Glucocorticoide in einer Modified Release-Formulierung
DE10014588A1 (de) 2000-03-27 2001-10-04 Basf Ag Wirkstoffhaltige Schwimmformen enthaltend Polyvinylacetat und Polyvinylpyrrolidon, deren Verwendung und Herstellung
DE10015479A1 (de) 2000-03-29 2001-10-11 Basf Ag Feste orale Darreichungsformen mit retardierter Wirkstofffreisetzung und hoher mechanischer Stabilität
US20020028240A1 (en) 2000-04-17 2002-03-07 Toyohiro Sawada Timed-release compression-coated solid composition for oral administration
WO2001080824A2 (fr) 2000-04-19 2001-11-01 Eurand America, Inc. Formes de dosage a liberation a modifiee a double mecanisme pour medicaments faiblement doses
DE10029201A1 (de) 2000-06-19 2001-12-20 Basf Ag Verfahren zur Herstellung fester oraler Darreichungsformen mit retardierender Wirkstoffreisetzung
US6476006B2 (en) 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
US6720005B1 (en) 2000-07-07 2004-04-13 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Coated, platform-generating tablet
US20040033267A1 (en) 2002-03-20 2004-02-19 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US6620439B1 (en) 2000-10-03 2003-09-16 Atul M. Mehta Chrono delivery formulations and method of use thereof
US6589562B1 (en) 2000-10-25 2003-07-08 Salvona L.L.C. Multicomponent biodegradable bioadhesive controlled release system for oral care products
US6887493B2 (en) 2000-10-25 2005-05-03 Adi Shefer Multi component controlled release system for oral care, food products, nutraceutical, and beverages
US6565873B1 (en) 2000-10-25 2003-05-20 Salvona Llc Biodegradable bioadhesive controlled release system of nano-particles for oral care products
HUP0501071A3 (en) 2001-03-13 2007-06-28 Penwest Pharmaceutical Co Chronotherapeutic dosage forms
ATE477804T1 (de) 2001-03-15 2010-09-15 Soligenix Inc Verfahren zur behandlung von entzündlichen erkrankungen des verdauungstrakts mit topisch wirksamen kortikosteroiden
IN191028B (fr) 2001-05-17 2003-09-13 Sun Pharmaceutical Ind Ltd
WO2003004009A1 (fr) 2001-07-02 2003-01-16 Geneva Pharmaceuticals, Inc. Formulation a compression directe de medicaments faiblement compressibles tels que le chlorhydrate de metformine
CN1520286B (zh) 2001-07-04 2010-12-01 太阳医药工业有限公司 胃滞留控制药物释出系统
US7163700B2 (en) 2001-07-31 2007-01-16 Capricorn Pharma, Inc. Amorphous drug beads
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
EP1429739A1 (fr) 2001-09-21 2004-06-23 Egalet A/S Systeme de liberation a base de polymere
WO2003024430A1 (fr) 2001-09-21 2003-03-27 Egalet A/S Systeme a liberation de polymere de morphine
CN1638740A (zh) 2001-09-28 2005-07-13 麦克内尔-Ppc股份有限公司 释出得到修饰的剂型
PT1443912E (pt) 2001-10-12 2007-11-28 Elan Pharma Int Ltd Composições tendo uma combinação de características de libertação imediata e de libertação controlada
US20080145438A1 (en) 2001-12-20 2008-06-19 Beuford Arlie Bogue Micro- and nano-particulate drugs and methods of making thereof
EP1465596A1 (fr) 2002-01-18 2004-10-13 Control Delivery Systems, Inc. Systeme de gel polymere pour administration regulee de medicaments combines
US20030215513A1 (en) 2002-02-21 2003-11-20 Peter Fyhr Method for releasing nanosized particles of an active substance from a diffusion-controlled pharmaceutical composition for oral use
AU2003213338A1 (en) 2002-03-14 2003-09-22 Daiichi Suntory Pharma Co., Ltd. Tablet containing pilsicainide hydrochloride (dry)
US7074426B2 (en) 2002-03-27 2006-07-11 Frank Kochinke Methods and drug delivery systems for the treatment of orofacial diseases
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US20040062778A1 (en) 2002-09-26 2004-04-01 Adi Shefer Surface dissolution and/or bulk erosion controlled release compositions and devices
NZ538842A (en) 2002-09-28 2008-03-28 Mcneil Ppc Inc Immediate release dosage form comprising a solid core of density 0.9 g/ml surrounded by a shell that is readily soluble to gastrointestinal fluids
US20080220074A1 (en) 2002-10-04 2008-09-11 Elan Corporation Plc Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
US7704527B2 (en) 2002-10-25 2010-04-27 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
US20040121010A1 (en) * 2002-10-25 2004-06-24 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
US20040156895A1 (en) 2002-11-12 2004-08-12 Elan Pharma International Ltd. Solid dosage forms comprising pullulan
US20040185097A1 (en) 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
US20070148229A1 (en) 2003-04-24 2007-06-28 Jagotec Ag Tablet with coloured core
BRPI0409652A (pt) * 2003-04-24 2006-04-25 Jagotec Ag tablete, embalagem farmacêutica, método de tratamento de doenças, e, método de preparação de um tablete
US20060177507A1 (en) 2003-05-22 2006-08-10 Joaquina Faour Controlled release device containing lercanidipine
UY28326A1 (es) 2003-05-22 2004-06-30 Osmotica Argentina S A Dispositivo de ruptura de liberacion controlada con un pasaje preformado
US8029822B2 (en) 2003-05-22 2011-10-04 Osmotica Kereskedelmi és Seolgáltató KFT Rupturing controlled release device having a preformed passageway
JP2007001865A (ja) 2003-09-16 2007-01-11 Ltt Bio-Pharma Co Ltd 脂溶性薬物封入微粒子、その製造法およびそれを含有する製剤
EP1663156A2 (fr) 2003-09-19 2006-06-07 Penwest Pharmaceuticals Company Formes de dosage chronotherapeutique
DE102004035936A1 (de) 2004-07-23 2006-03-16 Röhm GmbH & Co. KG Mehrschichtige Arzneiform
KR101363563B1 (ko) * 2004-09-10 2014-02-14 자고텍 아게 활성성분의 부위 및 시간 제어적 위장관 방출 정제
DE102004043863A1 (de) 2004-09-10 2006-03-16 Nitec Pharma Ag Tabletten mit orts- und zeitgesteuerter Wirkstofffreisetzung im Gastrointestinum
GB0427455D0 (en) 2004-12-15 2005-01-19 Jagotec Ag Dosage forms
EP1861072A2 (fr) 2005-03-14 2007-12-05 Massachusetts Institute Of Technology Nanocellules pour le diagnostic et le traitement de maladies et troubles
US9149439B2 (en) 2005-03-21 2015-10-06 Sandoz Ag Multi-particulate, modified-release composition
WO2007002597A2 (fr) 2005-06-27 2007-01-04 Biovail Laboratories International S.R.L. Formulations a liberation modifiee d'un sel de bupropion
EP1898886B1 (fr) 2005-07-01 2019-09-04 Rubicon Research Pvt Ltd. Nouvelle forme posologique a liberation soutenue
WO2007052299A2 (fr) 2005-08-24 2007-05-10 Rubicon Research Pvt Ltd. Formulation pour liberation controlee
FR2891459B1 (fr) 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
US9125833B2 (en) 2005-11-02 2015-09-08 Relmada Therapeutics, Inc. Multimodal abuse resistant and extended release opioid formulations
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US20120121653A1 (en) 2005-12-02 2012-05-17 Elan Pharma International Limited Novel mometasone compositions and methods of making and using the same
JP2009543797A (ja) 2006-07-10 2009-12-10 エラン ファーマ インターナショナル，リミティド ナノ粒子ソラフェニブ製剤
US20080014272A1 (en) 2006-07-11 2008-01-17 Phil Skolnick Compositions and Methods for Treatment of Chronic Pain Conditions
US20080026040A1 (en) 2006-07-31 2008-01-31 Isaac Farr Active agent-releasing dosage forms
PT2049123E (pt) 2006-08-03 2013-03-06 Horizon Pharma Ag Tratamento de doença reumatóide com glucocorticóide de libertação retardada
WO2008016729A1 (fr) 2006-08-04 2008-02-07 Nastech Pharmaceutical Company Inc. Compositions pour administration intranasale d'insuline humaine et leurs utilisations
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
AU2007291509B2 (en) 2006-08-30 2013-05-02 Jagotec Ag Controlled release oral dosage formulations comprising a core and one or more barrier layers
WO2008028193A2 (fr) 2006-09-01 2008-03-06 Pharmion Corporation Formulations orales d'analogues de cytidine administrées dans le côlon
US20080166303A1 (en) 2006-09-08 2008-07-10 Dov Tamarkin Colored or colorable foamable composition and foam
WO2008033351A2 (fr) 2006-09-11 2008-03-20 Theraquest Biosciences, Inc. Formulations multimode de libération prolongée et résistantes à l'abus
EP2097086A4 (fr) 2006-11-14 2012-01-11 Yissum Res Dev Co Compositions pour verres de contact
WO2008079963A2 (fr) 2006-12-22 2008-07-03 Cambrex Charles City, Inc. Compositions pharmaceutiques comprenant des complexes ioniques d'ingrédients pharmaceutiques actifs
WO2008085484A2 (fr) 2006-12-28 2008-07-17 Jacobus Pharmaceutical Company, Inc. Procédé de traitement de l'affection abdominale inflammatoire
GB2445539A (en) 2006-12-29 2008-07-16 Ardana Bioscience Ltd Bigel composition
WO2008094877A2 (fr) 2007-01-30 2008-08-07 Drugtech Corporation Compositions pour l'administration orale de produits pharmaceutiques
US20100016322A1 (en) 2007-02-28 2010-01-21 Nagesh Nagaraju Water Dispersible Pharmaceutical Formulation and Process for Preparing The Same
US20090068236A1 (en) 2007-04-13 2009-03-12 Chemgenex Pharmaceuticals, Inc. Oral Cephalotaxine Dosage Forms
BRPI0809282B8 (pt) 2007-04-13 2021-05-25 Dow Global Technologies Inc material granular, material de partida para uma forma de dosagem, forma de dosagem, processo de compressão direta para preparar uma forma de dosagem, uso do material granular e processo para granular um pó de polímero
WO2008140459A1 (fr) 2007-05-16 2008-11-20 Fmc Corporation Forme solide
US20080286343A1 (en) 2007-05-16 2008-11-20 Dzenana Cengic Solid form
US20080311162A1 (en) 2007-05-16 2008-12-18 Olivia Darmuzey Solid form
WO2008140460A1 (fr) 2007-05-16 2008-11-20 Fmc Corporation Forme solide
DK2167033T3 (en) 2007-05-30 2017-08-14 Veloxis Pharmaceuticals As Once daily oral dosage form comprising tacrolism
AU2008258596B2 (en) 2007-06-04 2013-02-14 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
EP2008651A1 (fr) 2007-06-26 2008-12-31 Drug Delivery Solutions Limited Patch bioérodable
WO2009022355A1 (fr) 2007-08-13 2009-02-19 Panacea Biotec Limited Compositions à libération prolongée comprenant du mycophénolate de sodium et procédés les concernant
HUE043897T2 (hu) 2007-09-25 2019-09-30 Solubest Ltd Lipofil hatóanyagot tartalmazó készítmények és eljárás elõállításukra
WO2009042778A1 (fr) 2007-09-25 2009-04-02 Nirmal Mulye Compositions pharmaceutiques à libération contrôlée
AR068745A1 (es) 2007-10-08 2009-12-02 Panacea Biotec Ltd Una composicion en forma de dosificacion farmaceutica oral de unidad de alta dosis de micofenolato sodico, metodo para utilizar dicha composicion y sus usos
WO2009047802A2 (fr) 2007-10-10 2009-04-16 Lupin Limited Nouvelle formulation bioadhésive à libération modifiée d'acide 5-aminosalicylique ou de ses sels et de ses métabolites destinée au traitement du colon
US20090123390A1 (en) 2007-11-13 2009-05-14 Meritage Pharma, Inc. Compositions for the treatment of gastrointestinal inflammation
US20110092449A1 (en) 2007-12-21 2011-04-21 Bradford James Duft Treatment of fibrotic conditions
EP2252320A2 (fr) 2007-12-21 2010-11-24 Coda Therapeutics, Inc. Utilisation de polynucléotides anti-connexine pour le traitement de cicatrices anormales ou excessives
EP2242844A2 (fr) 2007-12-21 2010-10-27 Coda Therapeutics, Inc. Utilisation de peptides anti-conenxines, seuls ou combinés à des polynucléotides anti-connexine, pour le traitement des maladies orthopédiques
WO2009110005A2 (fr) 2008-03-05 2009-09-11 Panacea Biotec Limited Compositions pharmaceutiques à libération modifiée comprenant du mycophénolate et procédés pour celles-ci
US8648119B2 (en) 2008-05-23 2014-02-11 Otonomy, Inc. Controlled release immunomodulator compositions and methods for the treatment of otic disorders
WO2009142772A2 (fr) 2008-05-23 2009-11-26 Mastcell Pharmaceuticals, Inc. Méthodes et traitement d’allergies et inflammations associées à des pathologies gastro-intestinales
WO2010005687A1 (fr) 2008-06-12 2010-01-14 University Of Alabama Huntsville Compositions comprenant de l’oxyde nitrique ou des donneurs d’oxyde nitrique dans le traitement de maladies neurodégénératives de traumatisme
GB2460915B (en) 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
CL2009001884A1 (es) 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
TWI494108B (zh) 2009-01-26 2015-08-01 Nitec Pharma Ag 糖皮質激素用以製備嚴重夜間氣喘用之於延遲釋放型的藥物之用途
NZ582836A (en) 2009-01-30 2011-06-30 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage

Also Published As

Publication number Publication date
SG174026A1 (en) 2011-09-29
JP2009545546A (ja) 2009-12-24
DK2049123T3 (da) 2013-03-04
MY149863A (en) 2013-10-31
SG10201503411QA (en) 2015-06-29
EP2049123B2 (fr) 2016-08-24
BRPI0717052A2 (pt) 2013-10-15
EP2049123B1 (fr) 2012-11-28
RS52672B2 (sr) 2018-03-30
AU2007280636A1 (en) 2008-02-07
HRP20130148T4 (hr) 2016-10-07
UA96457C2 (ru) 2011-11-10
PL2049123T3 (pl) 2013-04-30
EA015304B1 (ru) 2011-06-30
KR20090045149A (ko) 2009-05-07
AU2007280636B2 (en) 2013-07-18
US20080076743A1 (en) 2008-03-27
NO20090958L (no) 2009-04-30
PL2049123T5 (pl) 2017-09-29
HRP20130148T1 (en) 2013-03-31
DK2049123T4 (en) 2016-11-28
US20170281648A1 (en) 2017-10-05
ZA200809858B (en) 2009-10-28
IL195155A (en) 2016-05-31
SI2049123T1 (sl) 2013-04-30
US9504699B2 (en) 2016-11-29
SI2049123T2 (sl) 2016-10-28
TNSN08385A1 (en) 2009-12-29
ES2400446T3 (es) 2013-04-09
EP2049123A1 (fr) 2009-04-22
RS52672B (en) 2013-06-28
IL195155A0 (en) 2009-09-22
US20150141388A1 (en) 2015-05-21
CN101466385A (zh) 2009-06-24
US20120070499A1 (en) 2012-03-22
WO2008015018A1 (fr) 2008-02-07
ES2400446T5 (es) 2017-03-13
EA200900259A1 (ru) 2009-06-30
HK1130423A1 (en) 2009-12-31
MX2009001248A (es) 2009-02-11
US20140065214A1 (en) 2014-03-06
CA2655682A1 (fr) 2008-02-07
KR101430089B1 (ko) 2014-08-13
PT2049123E (pt) 2013-03-06
CN101466385B (zh) 2014-01-08
US8920838B2 (en) 2014-12-30

Similar Documents

Publication Publication Date Title
MA30665B1 (fr) Traitement de maladies rhumatoïdes avec des glucocorticoïdes a liberation retardee.
LTPA2017009I1 (lt) Brutono tirozinkinazės inhibitoriai
MA32872B1 (fr) Traitement du diabete chez des patients dont la regulation glycemique est insuffisante malgre une therapie par un medicament antidiabetique oralou non oral
BRPI0504758A (pt) miméticos de interleucina-8 e métodos para usá-los em prevenção, tratamento, diagnóstico, e melhora dos sintomas de uma doença
MA29722B1 (fr) Schema posologique pour le prasugrel
EP1543158A4 (fr) Compositions th rapeutiques aptam riques r gul es
ATE495750T1 (de) Sulfatide zur behandlung von autoimmunkrankheiten